Physician
Ona, Maria
Ona, Maria was paid $1.72M by Medicaid between Jan 2018 and Dec 2024, across 63 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 24% of everything it billed.
33Billing provider infoONA, MARIA
FRANKLIN, VA 23851
FRANKLIN, VA 23851
33aNPI1851305510assigned 07/28/2006
33bProvider typePediatrics Physician
28Total paid$1.72M
24GClaims53,901
24DCodes billed63
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Virginia
Rank by total paid#97 of 817
Median peer was paid$29K
This provider vs. median59×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,765 | $240K | |
| 2019 | 6,979 | $239K | |
| 2020 | 5,899 | $219K | |
| 2021 | 6,492 | $227K | |
| 2022 | 7,160 | $233K | |
| 2023 | 10,991 | $306K | |
| 2024incomplete | 9,615 | $258K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 7,123 | 6,392 | $419K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 3,354 | 3,157 | $285K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 13% | 2,831 | 2,716 | $221K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 9.7% | 2,314 | 2,116 | $167K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 9.5% | 2,278 | 2,018 | $164K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.5% | 1,487 | 1,328 | $113K |
| 90671 | 2.4% | 532 | 504 | $42K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.0% | 4,109 | 3,830 | $35K |
| 90670 | 1.6% | 1,239 | 1,142 | $28K | |
| 90651 | 1.2% | 630 | 589 | $21K | |
| 90680 | 1.1% | 1,033 | 937 | $20K | |
| 90698 | <1% | 816 | 755 | $15K |
51 more codes
| 99199 | Unlisted special service, procedure or report | <1% | 5,808 | $15K |
| 90716 | <1% | 648 | $13K | |
| 90688 | <1% | 1,130 | $13K | |
| 99188 | <1% | 569 | $12K | |
| 90674 | <1% | 512 | $12K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 308 | $11K |
| 90707 | <1% | 662 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 854 | $10K |
| 90619 | <1% | 234 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 722 | $10K |
| 81002 | <1% | 3,766 | $10K | |
| 90633 | <1% | 721 | $9K | |
| 99173 | <1% | 3,722 | $7K | |
| 90687 | <1% | 424 | $5K | |
| 90734 | <1% | 177 | $4K | |
| 96160 | <1% | 1,744 | $3K | |
| 92587 | <1% | 281 | $3K | |
| 90677 | <1% | 33 | $3K | |
| 96127 | <1% | 570 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 163 | $3K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 329 | $3K |
| 90697 | <1% | 61 | $3K | |
| 90685 | <1% | 231 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 54 | $2K |
| 90686 | <1% | 190 | $2K | |
| 90648 | <1% | 180 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 72 | $2K |
| 0072A | <1% | 37 | $1K | |
| 0071A | <1% | 28 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 66 | $1K |
| 99174 | <1% | 182 | $894.35 | |
| 90715 | <1% | 58 | $768.84 | |
| 99381 | <1% | 18 | $757.26 | |
| 85018 | <1% | 221 | $549.01 | |
| 90744 | <1% | 45 | $546.47 | |
| 90700 | <1% | 41 | $537.90 | |
| 0051A | <1% | 16 | $463.30 | |
| 0052A | <1% | 13 | $463.30 | |
| 90696 | <1% | 26 | $348.40 | |
| 83655 | <1% | 14 | $189.62 | |
| 90661 | <1% | 20 | $178.00 | |
| 99000 | <1% | 113 | $148.12 | |
| 36416 | <1% | 184 | $137.94 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 105 | $80.27 |
| 96161 | <1% | 36 | $67.52 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 519 | $41.69 |
| 90461 | <1% | 32 | $13.08 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 65 | $2.60 |
| 91307 | 0% | 102 | $0.00 | |
| 91305 | 0% | 35 | $0.00 | |
| 91308 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.